FindMyRecallSubscribe
Class I: serious health riskTerminated

AvKARE Atovaquone Oral Suspension Recall

Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx On…

AvKARE · Pulaski, TN

Risk level
Class I
Reported by FDA
Apr 24, 2024
Recall ID
D-0444-2024
Check your lot numberHow we source this data

Summary

AvKARE recalled Atovaquone Oral Suspension starting Mar 28, 2024. The FDA classified it as Class I (serious health risk) and published enforcement report D-0444-2024 on Apr 24, 2024. Reason: Microbial contamination of a non-sterile product: potential Bacillus cereus contamination. Status: Terminated.

Why it was recalled

Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

Product description

Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.

Lot numbers, UPCs & expiration codes

Lot: AW0221A Exp. 08/30/2025

Where it was sold

US Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0444-2024
Classification
Class I
Status
Terminated
Recall initiated
Mar 28, 2024
FDA report date
Apr 24, 2024
Quantity
153 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
AvKARE

Original FDA data

Every field from FDA enforcement report D-0444-2024, exactly as published.

Show all FDA fields
City
Pulaski
State
TN
Status
Terminated
Country
United States
Event ID
94329
Address
615 N 1st St
Code information
Lot: AW0221A Exp. 08/30/2025
Postal code
38478-2403
Report date
Apr 24, 2024
Product type
Drugs
Recall number
D-0444-2024
Classification
Class I
Recalling firm
AvKARE
Product quantity
153 cartons
Termination date
Aug 23, 2024
Reason for recall
Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.
Distribution pattern
US Nationwide.
Recall initiation date
Mar 28, 2024
Initial firm notification
Letter
Center classification date
Apr 16, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0444-2024, published Apr 24, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls